| |
|
|
|
CfPA - The Center for Professional Advancement, New Brunswick, NJ
October 9-11, 2013
Who Should Attend
This is an introductory-level course for the non-specialist interested in learning the basics of biotechnology. It presents essential information for personnel involved in, or contemplating participation in, biochemically-related and biotechnological research, supervision, scale-up or manufacture. It is most useful for:
• Non-specialist Scientific Personnel
• Engineers
• Chemists
• Technical Operations Personnel
• Lawyers
This course is not intended for those with extensive background in the field. Description
With the rapid developments in genetic engineering, it has become increasingly important to have a firm background in the basics pertaining to this area of research and technology.
This 3-day intensive course is designed to provide these fundamentals. The course will present the properties and manipulation of genetic material and will examine the primary gene product–the protein. Details of current approaches for making recombinant DNA and its use will be emphasized. Participants will be introduced to the fundamentals of genetic engineering through a study of molecular biology pertaining to the biochemistry of DNA and RNA, their structure and synthesis. Transfer of genetic information and its expression into product will provide the necessary background for the study of genetic engineering techniques. The course will focus on the basics of cutting and splicing DNA (gene cloning) and of introducing recombinant DNA into cells for expression into product. The state-of-the-art techniques for manufacturing and purifying a product will also be presented.
|
|
|
|
|
|
|
|
Organized by:
|
|
CfPA - The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
Ronald A. Pepin, Ph.D.; Senior Vice President, Business Development and Chief Business Officer, Celldex Therapeutics, Inc
Dr. Ronald A. Pepin is Senior Vice President and Chief Business Officer at Celldex Therapeutics, an antibody-based combination immunotherapy company. Celldex is discovering and developing innovative targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. Dr. Pepin was previously the SVP of Business Development at Medarex before its acquisition by Bristol-Myers Squibb. He was instrumental in the strategy and success of Yervoy, a novel treatment for melanoma. He also served as the Executive Director of External Science and Technology at Bristol-Myers Squibb Company where he was involved in forging Bristol-Myers Squibb's alliances with biotechnology companies. Dr. Pepin received his B.A. degree in biology at Tufts University and his Ph.D. in genetics from Georgetown University.
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
sberg@cfpa.com
|
|
|
|
|
|
|
|
|